Posts by: Patricia Inacio, PhD

News

Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and ... Read more

September 3, 2019

Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows

News

A combination of tremelimumab plus Imfinzi (durvalumab) is no better than standard chemotherapy at extending the survival of people with metastatic non-small cell lung cancer (NSCLC) with a high ... Read more

August 30, 2019

Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says

News

Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the ... Read more

August 20, 2019

INmune Bio Shares Early Results of Phase 1 Trial of INB03 for Advanced Cancer Treatment

News

INmune Bio’s therapy candidate INB03 is well-tolerated and has shown signs of activity in patients with advanced cancers, according to preliminary findings from a Phase 1 clinical trial. The early ... Read more

August 9, 2019

Upcoming Phase 2 Trial Will Test Opdivo-MTG201 Combo for Malignant Pleural Mesothelioma

News

An upcoming Phase 2 trial will explore the safety and effectiveness of a combo therapy — Opdivo (nivolumab) and MTG201 – for the treatment of malignant pleural mesothelioma. The ... Read more

July 30, 2019August 26, 2019

ONCOS-102, Keytruda Combo May Reduce Tumor Size in Treatment-resistant Melanoma, Early Trial Data Show

News

Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest. The trial is ... Read more

July 10, 2019

Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors

News

Immunophotonics and Clinical Laserthermia Systems (CLS) are teaming up in a Phase 1/2 trial to explore the safety and effectiveness of a thermal ablation approach — destruction of tissue ... Read more

July 2, 2019

DPX-Survivac-Keytruda Trio Shows Promise in DLBCL Patients

News

IMV‘s lead candidate, DPX-Survivac, in combination with Keytruda (pembrolizumab) and low-dose intermittent cyclophosphamide, eliminated radiologic traces of cancer cells in one-third of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more

June 28, 2019June 28, 2019

Complete Remission Induced in B-cell ALL Patients After Single Dose of FasT CAR-19 Therapy, Preliminary Data Show

News

A single infusion of an experimental cell therapy called FasT CAR-19 was well-tolerated and induced a complete remission in all B-cell acute lymphoblastic leukemia (B-ALL) patients included in a ... Read more

June 26, 2019

Tislelizumab Produces Promising Anti-Cancer Activity in Advanced Nasopharyngeal Cancer Patients, Preliminary Data Show

News

BeiGene’s investigational anti-PD-1 inhibitor tislelizumab is well-tolerated and showed early signs of efficacy in patients with advanced nasopharyngeal cancer, with more than 40% of patients achieving a response to ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia

Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows

Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says

INmune Bio Shares Early Results of Phase 1 Trial of INB03 for Advanced Cancer Treatment

Upcoming Phase 2 Trial Will Test Opdivo-MTG201 Combo for Malignant Pleural Mesothelioma

ONCOS-102, Keytruda Combo May Reduce Tumor Size in Treatment-resistant Melanoma, Early Trial Data Show

Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors

DPX-Survivac-Keytruda Trio Shows Promise in DLBCL Patients

Complete Remission Induced in B-cell ALL Patients After Single Dose of FasT CAR-19 Therapy, Preliminary Data Show

Tislelizumab Produces Promising Anti-Cancer Activity in Advanced Nasopharyngeal Cancer Patients, Preliminary Data Show

Pin It on Pinterest